Table 1.
Demographic and baseline characteristics of the patients.
| Total (N = 148) | GV1001 (N = 75) | Control (N = 73) | P value | |
|---|---|---|---|---|
| Age (years), mean (SD) | ||||
| Mean (SD) | 63.1 (9.1) | 64.2(8.7) | 62.0 (9.4) | 0.140 |
| Sex, n (%) | ||||
| Male | 80 (54.1) | 34 (45.3) | 46 (63.0) | 0.031 |
| Female | 68 (45.9) | 41 (54.7) | 27 (37.0) | |
| Smoking, n (%) | ||||
| Current | 19 (12.8) | 12 (16.0) | 7 (9.6) | 0.236 |
| Past | 50 (33.8) | 21 (28.0) | 29 (39.7) | |
| No | 79 (53.4) | 42 (56.0) | 37 (50.7) | |
| Alcohol, n (%) | ||||
| Current | 27 (18.2) | 12 (16.0) | 15 (20.6) | 0.193 |
| Past | 43 (29.1) | 18 (24.0) | 25 (34.3) | |
| No | 78 (52.7) | 45 (60.0) | 33 (45.2) | |
| Primary tumour site within pancreas | ||||
| Head | 71 (48.0) | 39 (52.0) | 32 (43.8) | 0.778 |
| Body | 43 (29.1) | 19 (25.3) | 24 (32.9) | |
| Tail | 23 (15.5) | 12 (16.0) | 11 (15.1) | |
| Overlapping | 11 (7.5) | 5 (6.7) | 6 (8.2) | |
| Pancreatic cancer status, n (%) | ||||
| Locally advanced | 36 (24.3) | 20 (26.7) | 16 (21.9) | 0.501 |
| Metastatic | 112 (75.7) | 55 (73.3) | 57 (78.1) | |
| Metastasis*, n (%) | ||||
| Lymph Node | 45 (30.4) | 20 (26.7) | 25 (34.2) | 0.769 |
| Bone | 3 (2.0) | 1 (1.3) | 2 (2.7) | |
| Liver | 88 (59.5) | 42 (56.0) | 46 (63.0) | |
| Lung | 18 (12.2) | 10 (13.3) | 8 (11.0) | |
| Brain | 0 (0) | 0 (0) | 0 (0) | |
| Others | 15 (10.1) | 4 (5.3) | 11 (15.1) | |
| CA 19-9 concentration (IU/L) | ||||
| Mean (SD) | 5229.0 (17,449.0) | 4032.5 (12,500.7) | 6458.2 (21,400.6) | 0.400 |
| ECOG performance status, n (%) | ||||
| 0 | 89 (60.1) | 45 (60.0) | 44 (60.3) | 0.769 |
| 1 | 55 (37.2) | 27 (36.0) | 28 (38.3) | |
| 2 | 4 (2.7) | 3 (4.0) | 1 (1.4) | |
SD standard deviation.
*Multiple organ metastases were counted separately.